Identification of potential mechanisms of Schisandrin B in the treatment of idiopathic pulmonary fibrosis by integrating network pharmacology and experimental validation
- 16 November 2024
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (5) , 5389-5403
Abstract
Idiopathic pulmonary fibrosis (IPF) is a worsening fibrotic condition characterized by a short survival rate and limited treatment options. This study evaluates the potential anti-fibrotic properties of Schisandrin B (Sch B) through network pharmacology and experimental validation. A mouse model of bleomycin-induced pulmonary fibrosis was established, and the modeled mice were treated with Sch B at three doses (20 mg/kg/day, 40 mg/kg/day, and 80 mg/kg/day). A fibrotic model was developed in NIH/3T3 cells by treating them with TGF-β (10 ng/mL) and administering Sch B at various concentrations (10, 20, and 40 µM). The results revealed that Sch B treatment delayed the development of bleomycin-induced pulmonary fibrosis and substantially decreased the transcription levels of collagen I and α-SMA in TGF-β-induced fibroblasts. Core targets were screened with protein-protein interaction network analysis, molecular complex detection (MCODE), and CytoHubba plugin. The application of Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and molecular docking highlighted the significance of the HIF-1α signaling pathway in the potential mechanism of Sch B in IPF therapy. Western blot, PCR, and immunofluorescence were performed to validate the effects of Sch B on HIF-1α. In vivo and in vitro, Sch B administration reduced HIF-1α expression. These outcomes provide valuable insights into the potential mechanism by which Sch B delays IPF development, with HIF-1α potentially serving as a key target. However, further investigation is warranted to assess the safety and efficacy of Sch B in clinical settings.Keywords
Funding Information
- Postgraduate Research and Practice Innovation Program of Jiangsu Province (SJCX24_0968, SJCX23_0783)
- Natural Science Foundation of Jiangsu Province (BK20240731)
- National Natural Science Foundation of China (82074358)
This publication has 47 references indexed in Scilit:
- Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial–mesenchymal transition in renal tubular cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- Idiopathic pulmonary fibrosisThe Lancet, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1American Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Murine models of pulmonary fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Comparative Expression Profiling in Pulmonary Fibrosis Suggests a Role of Hypoxia-inducible Factor-1α in Disease PathogenesisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- A novel experimental model of acute hypertriglyceridemia induced by schisandrin BEuropean Journal of Pharmacology, 2006
- Mechanisms of Pulmonary FibrosisAnnual Review of Medicine, 2004
- Simple method of estimating severity of pulmonary fibrosis on a numerical scale.Journal of Clinical Pathology, 1988
- BLEOMYCIN-INDUCED INTERSTITIAL PULMONARY-DISEASE IN THE NUDE, ATHYMIC MOUSE1979